Neurohormonal modulation in pulmonary arterial hypertension

Area of Science:

• Cardiovascular Medicine
• Pulmonary Medicine
• Pharmacology

Background:

• Pulmonary hypertension (PH) is a severe condition characterized by high pulmonary pressures, often leading to right heart failure.
• Pulmonary arterial hypertension (PAH), a form of PH, involves progressive remodeling and obstruction of small pulmonary arteries.
• Neurohormonal imbalances are linked to poorer prognosis and survival in PAH patients.

Purpose of the Study:

• To provide an overview of current and potential neurohormonal modulation strategies for PAH.
• To highlight the challenges in translating preclinical findings to clinical application in PAH.
• To propose improved approaches for neurohormonal modulation in PAH treatment.

Main Methods:

• Review of preclinical and clinical studies on pharmacological and nonpharmacological neurohormonal modulation in PAH.
• Analysis of the limitations in understanding neurohormonal system changes during PAH progression.
• Discussion of challenges in animal model to human trial translation for PAH therapies.

Main Results:

• Current neurohormonal modulation benefits in PAH are limited due to incomplete understanding of disease-related neurohormonal changes.
• Difficulties exist in translating findings from animal models to effective human PAH treatments.
• Individualized and longitudinal assessment of neurohormonal status is proposed as a key improvement.

Conclusions:

• Improved timing and specificity of neurohormonal modulation strategies are necessary for better PAH outcomes.
• Longitudinal and individualized neurohormonal assessments are crucial for optimizing PAH treatment.
• Advanced imaging techniques like positron emission tomography may aid in determining neurohormonal status and optimizing treatment in PAH patients across different disease stages.